Lysozyme increases bactericidal activity of ceragenin CSA-13 against Bacillus subtilis
暂无分享,去创建一个
P. Savage | K. Fiedoruk | R. Bucki | E. Piktel | M. Cieśluk | P. Deptuła | G. Król | B. Durnaś
[1] K. Majewski,et al. Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections , 2018, Central-European journal of immunology.
[2] Anthony D. Kappell,et al. Poultry and beef meat as potential seedbeds for antimicrobial resistant enterotoxigenic Bacillus species: a materializing epidemiological and potential severe health hazard , 2018, Scientific Reports.
[3] A. Brisabois,et al. Bacillus cereus, a serious cause of nosocomial infections: Epidemiologic and genetic survey , 2018, PloS one.
[4] Juan Wang,et al. Prevalence, Virulence Genes, Antimicrobial Susceptibility, and Genetic Diversity of Bacillus cereus Isolated From Pasteurized Milk in China , 2018, Front. Microbiol..
[5] W. Kamysz,et al. Activity of antimicrobial peptides and conventional antibiotics against superantigen positive Staphylococcus aureus isolated from patients with atopic dermatitis , 2018, Postepy dermatologii i alergologii.
[6] Nguyen Bao Hung,et al. Extrachromosomal expression of nat05 gene encoding an alkaline serine protease from Bacillus subtilis N05 , 2018 .
[7] A. K. Criss,et al. From bacterial killing to immune modulation: Recent insights into the functions of lysozyme , 2017, PLoS pathogens.
[8] P. Savage,et al. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo , 2017, BMC Microbiology.
[9] P. Savage,et al. Ceragenins as Mimics of Endogenous Antimicrobial Peptides , 2017 .
[10] K. Pogoda,et al. Sporicidal activity of ceragenin CSA-13 against Bacillus subtilis , 2017, Scientific Reports.
[11] K. Pogoda,et al. Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites , 2016, PloS one.
[12] H. Çam,et al. Successful Treatment of Bacillus cereus Bacteremia in a Patient with Propionic Acidemia , 2016, Case reports in pediatrics.
[13] V. Kandi. Clinical Significance of Bacillus Species Other than Bacillus anthracis , 2016 .
[14] A. Sotto,et al. Bacillus cereus infection: 57 case patients and a literature review. , 2015, Medecine et maladies infectieuses.
[15] E. Giralt,et al. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates. , 2015, International journal of antimicrobial agents.
[16] Tobias Bollenbach,et al. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. , 2015, Current opinion in microbiology.
[17] P. Janmey,et al. Bactericidal Activities of Cathelicidin LL-37 and Select Cationic Lipids against the Hypervirulent Pseudomonas aeruginosa Strain LESB58 , 2015, Antimicrobial Agents and Chemotherapy.
[18] Xiaoxiang Hu,et al. Expression of Recombinant Human Lysozyme in Egg Whites of Transgenic Hens , 2015, PloS one.
[19] M. Azizi,et al. Molecular Diagnosis and Characterization of Bacillus subtilis Isolated from Burn Wound in Iran , 2014 .
[20] Bingqian Liu,et al. Causative organisms of post-traumatic endophthalmitis: a 20-year retrospective study , 2014, BMC Ophthalmology.
[21] P. Savage,et al. Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients , 2014, BioMed research international.
[22] P. Janmey,et al. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. , 2013, The Journal of antimicrobial chemotherapy.
[23] Min Jin Kim,et al. Combined Bacillus licheniformis and Bacillus subtilis infection in a patient with oesophageal perforation. , 2012, Journal of medical microbiology.
[24] P. Savage,et al. In vitro Activities of the Novel Ceragenin CSA-13, Alone or in Combination with Colistin, Tobramycin, and Ciprofloxacin, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients , 2012, Chemotherapy.
[25] P. Janmey,et al. Potential of ceragenin CSA‐13 and its mixture with pluronic F‐127 as treatment of topical bacterial infections , 2011, Journal of applied microbiology.
[26] Y. Hirai,et al. Bacillus cereus bacteremia outbreak due to contaminated hospital linens , 2011, European Journal of Clinical Microbiology & Infectious Diseases.
[27] P. Janmey,et al. Modulation of exogenous antibiotic activity by host cathelicidin LL‐37 , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[28] R. Epand,et al. Depolarization, Bacterial Membrane Composition, and the Antimicrobial Action of Ceragenins , 2010, Antimicrobial Agents and Chemotherapy.
[29] J. Bader,et al. Anti-Trypanosomatid Activity of Ceragenins , 2010, The Journal of parasitology.
[30] E. Bottone. Bacillus cereus, a Volatile Human Pathogen , 2010, Clinical Microbiology Reviews.
[31] S. Ha,et al. Synergistic effects of ethanol and UV radiation to reduce levels of selected foodborne pathogenic bacteria. , 2010, Journal of food protection.
[32] Chris W. Michiels,et al. Lysozymes in the animal kingdom , 2010, Journal of Biosciences.
[33] C. López-Cabezas,et al. Antibiotics in endophthalmitis: microbiological and pharmacokinetic considerations. , 2010, Current clinical pharmacology.
[34] P. Savage,et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. , 2009, The Journal of investigative dermatology.
[35] P. Savage,et al. Activities of Ceragenin CSA-13 Against Established Biofilms in an In Vitro Model of Catheter Decolonization , 2009 .
[36] A. Fouet,et al. Biofilm Formation and Cell Surface Properties among Pathogenic and Nonpathogenic Strains of the Bacillus cereus Group , 2009, Applied and Environmental Microbiology.
[37] Ronald N. Jones,et al. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. , 2007, The Journal of antimicrobial chemotherapy.
[38] M. Gilmore,et al. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. , 2005, Investigative ophthalmology & visual science.
[39] D. T. Liu,et al. Infective endophthalmitis caused by Bacillus cereus after cataract extraction surgery. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] P. Savage,et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. , 2002, Journal of medicinal chemistry.
[41] M. Welsh,et al. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[42] C. Foster,et al. Bacillus-induced endophthalmitis: new series of 10 cases and review of the literature. , 1990, The British journal of ophthalmology.
[43] D. Shlaes,et al. Serious Infections Caused by Bacillus Species , 1987, Medicine.
[44] R. Guillard,et al. Comparison between the folding of reduced hen egg white lysozyme and that of reduced human milk lysozyme. , 1982, Biochemistry.